Mar 28, 2022 / 04:30PM GMT
Paul Matteis - Stifel, Nicolaus & Company, Incorporated - Analyst
Great. Good afternoon, everybody, and thank you for continuing on here. It's always a pleasure to moderate panels with the Prothena team, Gene and Tran. So thank you guys as always. Gene, do you want to just kick it off and give some opening remarks on the recent Prothena updates and as brief as you can, so we can get into Q&A? Is that cool?
Gene Kinney - Prothena Corporation PLC - President & CEO, Director
You got it. Thanks, Paul. And thanks very much for having us. We always enjoy these discussions. So yeah, I mean, just very briefly for those that don't know Prothena well, we focus on diseases that are caused by dysregulation of protein, which takes us into two very important therapeutic areas of peripheral amyloid diseases. So these are diseases like AL amyloidosis, ATTR amyloidosis, and of course, central nervous system disorders here, diseases like Alzheimer's disease, Parkinson's disease and the like.
And so our portfolio is focused in those spaces. We have programs
Prothena Corporation PLC at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers